Plasmodium falciparum K13 mutations in Africa and Asia impact artemisinin resistance and parasite fitness
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
The emergence of mutant K13-mediated artemisinin (ART) resistance in Plasmodium falciparum malaria parasites has led to widespread treatment failures across Southeast Asia. In Africa, K13- propeller genotyping confirms the emergence of the R561H mutation in Rwanda and highlights the continuing dominance of wild-type K13 elsewhere. Using gene editing, we show that R561H, along with C580Y and M579I, confer elevated in vitro ART resistance in some African strains, contrasting with minimal changes in ART susceptibility in others. C580Y and M579I cause substantial fitness costs, which may slow their dissemination in high-transmission settings, in contrast with R561H that in African 3D7 parasites is fitness neutral. In Cambodia, K13 genotyping highlights the increasing spatio-temporal dominance of C580Y. Editing multiple K13 mutations into a panel of Southeast Asian strains reveals that only the R561H variant yields ART resistance comparable to C580Y. In Asian Dd2 parasites C580Y shows no fitness cost, in contrast with most other K13 mutations tested, including R561H. Editing of point mutations in ferredoxin or mdr2 , earlier associated with resistance, has no impact on ART susceptibility or parasite fitness. These data underline the complex interplay between K13 mutations, parasite survival, growth and genetic background in contributing to the spread of ART resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“k13 P574L mutations have each been shown to have multiple independent origins throughout SE Asia64 and have been reported in Africa65.”
From Rising prevalence of Plasmodium falciparum Artemisinin partial resistance mutations in Ethiopia (2025) · cites this paper as [64]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Artemisinin Resistance in Plasmodium falciparum Malaria
Dondorp, A. M., Nosten, F., Yi, P., Das, D., Phyo, A. P., Tarning, J., Lwin, K. M., Ariey, F., Hanpithakpong, W., Lee, S. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808859 · Cited by 3,424
Self-citationSpread of Artemisinin Resistance in Plasmodium falciparum Malaria
Ashley, E. A., Dhorda, M., Fairhurst, R. M., Amaratunga, C., Lim, P., Suon, S., Sreng, S., Anderson, J. M., Mao, S., Sam, B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314981 · Cited by 2,205 · cited 7×
“Association of mutations in the Plasmodium falciparum 718 Kelch13 gene (Pf3D7_1343700) with parasite clearance rates after artemisinin-based treatments—a 719 WWARN individual patient data meta-analysis.”
BackgroundInfluentialSelf-citation
Cited by
Rising prevalence of Plasmodium falciparum Artemisinin partial resistance mutations in Ethiopia
Brhane, B. G., Fola, A. A., Nigussie, H., Leonetti, A., Kassa, M., Hailgiorgis, H., Wuletaw, Y., Abera, A., Mohammed, H., Sime, H., et al. (2025) · Communications Medicine · doi:10.1038/s43856-025-01008-0 · Cited by 29
Nayak, S., Peto, T. J., Kucharski, M., Tripura, R., Callery, J. J., Quang Huy, D. T., Gendrot, M., Lek, D., Nghia, H. D. T., van der Pluijm, R. W., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54915-6 · Cited by 15
Mechanistic insights into dual-active liver and blood-stage antiplasmodials
(2025) · doi:10.1128/mbio.02423-25
Metadata
- Authors
- Stokes, B. H., Dhingra, S. K., Rubiano, K., Mok, S., Straimer, J., Gnädig, N. F., Deni, I., Schindler, K. A., Bath, J. R., Ward, K. E., Striepen, J., Yeo, T., Ross, L. S., Legrand, E., Ariey, F., Cunningham, C. H., Souleymane, I. M., Gansané, A., Nzoumbou-Boko, R., Ndayikunda, C., Kabanywanyi, A. M., Uwimana, A., Smith, S. J., Kolley, O., Ndounga, M., Warsame, M., Leang, R., Nosten, F., Anderson, T. J., Rosenthal, P. J., Ménard, D., & Fidock, D. A.
- Venue
- eLife
- Publisher
- eLife Sciences Publications, Ltd
- Published
- 2021-07-19
- Volume
- 10
- ISSN
- 2050-084X (ISSN-L)
- OpenAlex
- W3184715006
- Cited by
- 167
- References
- 2
- FWCI
- 22.27
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.